Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
about
Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplantIncidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adultsSurvival from childhood cancer in northern England, 1968-2005.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UKChildhood leukaemia: long-term excess mortality and the proportion 'cured'.Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin.Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trialOutcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology GroupEarly outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI.What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?Can anthracycline therapy for pediatric malignancies be less cardiotoxic?Pediatric acute myeloid leukemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.A critical review of which children with acute myeloid leukaemia need stem cell procedures.EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML).Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.Recruitment of childhood leukaemia patients to clinical trials in Great Britain during 1980-2007: variation by birth weight, congenital malformation, socioeconomic status and ethnicity.Survival from teenage and young adult cancer in Northern England, 1968-2008.Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years.Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo.Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.Invasive aspergillosis of the small bowel in an infant with acute myeloid leukemia and intestinal obstruction.Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.Prognosis of patients with t(8;16)(p11;p13) acute myeloid leukemia.Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children.WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group.Treatment of acute myeloid leukemia in children: experience from a tertiary care hematology centre in India.
P2860
Q30244600-2B8638A4-B1B2-422D-9DCD-3012BE9F10D2Q35189037-1A415D56-C566-4090-AA10-8B3652F0B419Q35563658-356BB8B9-C9EE-4C93-A96D-B9F5D95F0D27Q35568696-331167B0-BA37-4851-87F9-BEE629698618Q35620600-F092D9D3-3168-4790-B005-9AB85E0AB9CFQ35667279-CB6B372C-3522-44EE-9DA8-3792F75D7B7FQ36610199-DE884D28-F02B-462D-A3E6-70B39B3DE49DQ36755145-E491978B-3130-4DCC-BD70-6F78FD7FB13EQ37051056-64C539EC-8B6A-4ADE-B976-1023CAEF70A1Q37303824-5A76CFEB-B17C-48AD-B7FF-3FF315B3B212Q37324869-920FD7E0-3115-47A2-AFB6-12FC515683E0Q37427903-9A757657-32CA-4E9D-83F0-3C5A4BEBF17FQ37474194-E7C23D72-B4E0-4A18-AAB1-8EC0246DFF9CQ37560324-42745FAD-A964-4045-9464-00AC664B9E4AQ37785821-5B73BF56-98DF-43E6-870B-1677B955FC2DQ37988570-2C0FD6D4-9241-4BCF-9A66-3898EB201C1BQ38097334-78AF9C52-1887-4FF9-9CE6-AECE1B3A697BQ38102644-5A2B40B4-4A0E-4D2F-9834-ACDFCD7C07AEQ38155455-A4EB7990-B09C-4419-9DEE-7AFC913CF3A7Q38195065-DAA6FEB5-08C2-4EBC-B643-3DD1F30DED2EQ38196743-7108D450-49DB-444F-8273-CDA904B97A15Q38205864-90667E66-5D5D-4111-B051-E6A3A682681DQ38345216-10295E69-582C-4F20-AA47-F6F8740ECBCBQ38366487-B4641B4D-F7FC-4801-99C6-91ABA14AB441Q38881996-3924AE76-5E3C-4117-903F-86AE5101A650Q38902112-D313B12A-B3E3-44DB-B83A-D4FCA906E944Q39234466-0F51512D-5D5D-4336-B263-7F95BD3CD6ABQ39270284-509046CF-3B1D-4E2B-A58D-98941E1C104FQ39376553-F6751081-5923-417D-B4B6-7761B79C0996Q39477447-AFF648D8-E789-42C3-B89A-569BFFCC18B1Q39758498-5F653323-1209-4952-98C6-C294412B3C45Q40316983-A2AF2FBB-8294-4691-9D19-741A53AD6BC4Q40397551-6FBC41CF-26C3-4A77-AC11-048164E86DDAQ40681571-34142D24-BE83-45EB-8C27-54A22DEFA15EQ41348310-88C63646-F169-486C-BBDC-5EF8E08F8E4AQ41643112-4371F56B-6176-4421-945E-A6A4E18755A3Q43574379-6DD81634-33B4-4824-9FCA-4B95D5CFC519Q43928924-C879208B-987E-434B-BA5C-0EB007F25C5FQ44097808-F4F66338-3C10-4EED-AD1A-F5993BE2F1EBQ44126009-8886ABF7-92F8-49E5-BC13-5E74D3DF0678
P2860
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
description
im Dezember 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 December 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2005
@uk
name
Treatment strategy and long-te ...... d in consecutive UK AML trials
@en
Treatment strategy and long-te ...... d in consecutive UK AML trials
@nl
type
label
Treatment strategy and long-te ...... d in consecutive UK AML trials
@en
Treatment strategy and long-te ...... d in consecutive UK AML trials
@nl
prefLabel
Treatment strategy and long-te ...... d in consecutive UK AML trials
@en
Treatment strategy and long-te ...... d in consecutive UK AML trials
@nl
P2093
P2860
P356
P1433
P1476
Treatment strategy and long-te ...... d in consecutive UK AML trials
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403924
P577
2005-12-01T00:00:00Z